Biocon

Established in 1978, Biocon Limited, is India's largest, and Asia's leading, biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. We develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including MAbs, rh-insulin& Insulin Analogs. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG and India's first biologic BioMAb-EGFR; for head and neck cancer. It has now successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, being introduced as Alzumab; for psoriasis in India, in 2013. For more information, log on to: www.biocon.com

Advantage products:

Back List